Cargando…
Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer
Although the emergence of immunotherapy has broken the deadlock of extensive stage small cell lung cancer (ES‐SCLC), the study of markers for predicting efficacy is the key to the breakthrough of immunotherapy, and exploring more innovative, efficient and safe treatment models is also an important r...
Autores principales: | Cui, Yanan, Zhao, Peiyan, Cheng, Ying, Ren, Xiubao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067358/ https://www.ncbi.nlm.nih.gov/pubmed/36861174 http://dx.doi.org/10.1111/1759-7714.14837 |
Ejemplares similares
-
Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021) -
Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer
por: Wang, Zhizhen, et al.
Publicado: (2023) -
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
por: Hui, Zhenzhen, et al.
Publicado: (2015) -
Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer
por: Russell, Éilis, et al.
Publicado: (2022) -
Natural Killer Cells in the Lungs
por: Cong, Jingjing, et al.
Publicado: (2019)